Qiagen NV : QIAGEN and Bio-X Center collaborate to open translational medicine lab in Shanghai
03/22/2012| 03:59am US/Eastern
Recommend:
-
Collaboration aims to turn biological research into
diagnostics and drugs that optimize patient care
-
QIAGEN to provide state-of-the-art technologies and
platforms for gene mutation analysis and sample preparation
automation
-
QIAGEN to launch similar collaborations in other regions
throughout China
Shanghai, China, March 22, 2012 - QIAGEN today announced that
it has signed an agreement with Bio-X Center of Shanghai Jiao
Tong University to open a joint translational medicine lab in
Shanghai. The lab is the first of its kind between QIAGEN and
a major research institution in China and is a key milestone
in the Company's expansion in key emerging markets and as
a leading player in translational medicine.
"Translational Medicine aims to transform basic research
results into clinically applicable practices. The trend of
translational medicine is unstoppable and I think both
scientists and policy makers should adapt this new concept as
quick as possible and work together to improve human
health" remarked Professor He Lin, Director of the Bio-X
Center at Shanghai Jiao Tong University and a member of the
Chinese Academy of Sciences.
QIAGEN will provide the Center with Pyromark Q24MDx and
instruments and related products. The Pyromark system is a
state-of-the-art instrument which allows researchers to,
among many things, study gene mutations that play a role in
various diseases. By studying biomarkers and pathways,
researchers can turn viable disease related biomarkers into
clinically applicable molecular diagnostic assays. Bio-X
Center will use the instruments and QIAGEN reagents in a
variety of research fields including validation and analysis.
"Translational medicine is quickly becoming the future
of medicine by applying basic research to develop clinical
diagnostics and therapies that prevent disease and optimize
patient care," said Dr. Victor Shi, Asia Pacific
President of QIAGEN. "Through this agreement with the
Bio-X Center we can leverage our leading positions as a
solutions provider in biological research, drug discovery and
personalized healthcare to help develop better diagnostics
and therapies for the Chinese people."
QIAGEN technologies are a staple in sample preparation and
are playing an important role in driving the development of
the drug discovery and personalized healthcare markets.
QIAGEN offers proprietary systems for the automation of
entire workflows in all application areas and customer
segments. Through greater standardization, higher accuracy
and reproducibility of results and increased efficiency,
QIAGEN platforms are helping to drive the dissemination of
molecular testing technologies in healthcare around the
world.
About QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading
global provider of . Sample technologies are used to isolate
and process , and proteins from biological samples such as
blood or tissue. Assay technologies are used to make such
isolated bio-molecules visible. QIAGEN has developed and
markets more than 500 sample and assay products as well as
automated solutions for such . The company provides its
products to laboratories, academic researchers,
pharmaceutical and biotechnology companies, and customers for
purposes such as forensics, animal or food testing and
pharmaceutical process control. QIAGEN's assay
technologies include one of the broadest panels of molecular
diagnostic tests available worldwide. This panel includes the
digene Test, which is regarded as a "gold
standard" in testing for high-risk types of human
papillomavirus (), the primary cause of cervical cancer, as
well as a broad suite of solutions for infectious disease
testing and companion diagnostics. As of December 31, 2011,
QIAGEN employed nearly 3,900 people in over 35 locations
worldwide.http://www.qiagen.com/.
distributed by
|
This press release was issued by Qiagen NV and was initially posted at http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=374&lang=EN . It was distributed, unedited and unaltered, by noodls on 2012-03-22 09:54:50 AM. The issuer is solely responsible for the accuracy of the information contained therein.
|
Recommend :
